Day 1 – 21 September 2021
| 09:00–09:25 | Welcome Word |
| 09:25–09:30 | Break |
|
Interactive Poster session 1 Long-Term Value of the International IgAN Prediction Tool and the Role of Hematuria Transforming MEST-score to prognostic staging in IgA-nephropathy An increasing incidence of IgA nephropathy and Henoch-Schönlein purpura during the 23 years of biopsy survey in the Czech Republic A key role for soluble CD89 as inducer of mesangial proliferation in childhood IgA nephropathy Unravelling the complexity of pathogenic immune complexes in IgA nephropathy Probing IgA1 using selective digestion with the IgA1 protease from Streptococcus oralis to identify the pathogenic form of IgA1 in IgAN |
|
| 10:15–10:30 | Coffee Break |
| 10:30–11:30 | Industry Symposium 2 |
| 11:30–11:35 | Break |
| 11:35–12:25 |
Plenary Session 1 Human genetics of IgA system and IgA nephropathy RNA interference in IgAN Is there a link between collagen IV mutations and IgAN? |
| 12:25–12:50 | Lunch Break |
| 12:50–13:50 |
Free Communications 1 Impact of VIS649, an APRIL-Neutralizing IgG2 Monoclonal Antibody, on Tetanus- and Diphtheria-Toxoid Vaccination-Elicited Immune Responses in Healthy Volunteers: Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Low serum immunoglobulin G4 levels and its potential mechanism in IgA nephropathy Molecular Phenotyping of aberrant IgA1 O-glycosylation in serum of patients with IgA nephropathy Human Mesangial Cell Activation Induced by Endothelin-1 or IgA Nephropathy Patient-Derived Immune Complexes is Blocked by Selective ETA Antagonist Atrasentan A novel ELISA method to measure levels of IgA1-specific IgG antibodies |
| 13:50–13:55 | Break |
| 13:55–14:55 | Panel Discussion 1 Expert Panel: Living with IgAN and understanding what we can learn from the patient journey |
| 14:55–15:00 | Break |
| 15:00–15:30 | Industry Symposium 6a |
| 15:30–15:35 | Break |
| 15:35–16:25 |
Plenary Session 2 Complement in IgAN what we know and what we don't A role for the lectin pathway? The alternative pathway of complement activation in IgA nephropathy |
| 16:25–16:30 | Break |
| 16:30–17:20 |
Plenary Session 3 What next for the Oxford Classification? The use of Artificial Intelligence in kidney biopsy evaluation Single cell genomics and spatial transcriptomic technologies to understand kidney disease |
| 17:20–17:25 | Break |
| 17:25–18:10 |
Plenary Session 4 Fantastic IgA Plasma Cells and where to find them 25 years since IgA1 glycosylation changes were first described-what will the next 25 years bring? Is IgAN a disease of mistrafficking B cells? |
| 18:10–18:15 | Break |
| 18:15–19:15 | Industry Symposium 2 |
| 19:15–19:20 | Break |
| 19:20–20:20 | Industry Symposium 1 |
| 20:20–20:25 | Break |
| 20:25–21:10 |
Interactive Poster session 2 Integrin α1β1 is involved in mesangial-cell activation by IgA1-containing immune complexes from patients with IgA nephropathy Differential pathway activation in Ig-producing cells from IgAN patients and healthy controls mediated by cytokine stimulation Characterization of different molecular forms of aberrantly glycosylated IgA1 in the circulation of patients with IgA nephropathy A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults with IgA Nephropathy Clinical Pharmacology and Population Pharmacokinetic/Pharmacodynamic Modeling of Lectin Pathway Inhibition by Narsoplimab (OMS721) Quantitative Analysis of IgA1 O-glycoforms in Familial IgA Nephropathy |
|
All times in the symposium programme are in Central European Summer Time – CEST (UTC + 2). |
|
